Figure 3.

Ratio of agalactosylated to monogalactosylated N-glycans in serum (sG0/G1) does not predict therapeutic response. Baseline sG0/G1 stratified according to European League Against Rheumatism (EULAR) response category at 3 months polled from both Autoimmune Biomarkers Collaborative Network and Nested I cohorts. Mean ± SD for good responders 1.29 ± 0.35, moderate 1.35 ± 0.35, nonresponders 1.28 ± 0.44. P = ns for all comparisons.